Haplotypes encoding the factor VIII 1241Glu variation and the risk of myocardial infarction\ud by Nossent, A.Y. et al.
Haplotypes encoding the factor VIII 1241Glu variation and the
risk of myocardial infarction
A. Y . NOSSENT ,* J . C . J . E IK ENBOOM,* B . C . TAN IS ,* C. J . M. DOGGEN and F . R . ROSENDAAL*
*Department of Haematology, Haemostasis and Thrombosis Research Center, and Department of Clinical Epidemiology, Leiden University
Medical Center, Leiden, the Netherlands
To cite this article: Nossent AY, Eikenboom JCJ, Tanis BC, Doggen CJM, Rosendaal FR. Haplotypes encoding the factor VIII 1241Glu variation and
the risk of myocardial infarction. J Thromb Haemost 2007; 5: 619–21.
Elevated levels of coagulation factor (FVIII) are an important
risk factor for venous thrombosis [1–4]. FVIII activity
(FVIII:C) ‡150 IU dL)1 increases the risk of a first venous
thrombosis 5-fold compared to levels below 100 IU dL)1.
There are also indications that elevated FVIII levels contribute
to the risk of arterial thrombosis [5–11].
In 2003, Machiah et al. [12] reported a missense single
nucleotide polymorphism (SNP) in the X-chromosomal FVIII
gene, c94901 g, which causes an amino acid change in the
B-domain of FVIII, Asp1241Glu (D1241E). This amino acid
change was associated with a decrease in FVIII:C. Machiah et
al. found that this polymorphism accounts for approximately
5% of total variation in FVIII:C in the population of the
Genetic Analysis of Idiopathic Thrombophilia (GAIT) study
[12]. More recently, Scanavini et al. [13] reported that 1241E
was associated with an 11% reduction in FVIII:C in 145
healthy women and 150 women with venous thrombosis.
It is unclear by which mechanism the 1241E variant
influences the levels of FVIII. Scanavini et al. [13] hypothesized
that the variation was involved in activated protein C (APC)
resistance, but could not demonstrate this. On the website of
SeattleSNPs [14], SNP and haplotype data are presented for a
wide variety of genes, including the gene encoding FVIII. These
data are based on the re-sequencing of these genes in 23
subjects of European–American descent. In this population,
the SNP encoding 1241E is present in at least three different
haplotypes, HT1, HT3 and HT5, of which possibly only one is
responsible for the reported effects on FVIII levels.
Recently, we investigated the effects of these three haplo-
types on levels of FVIII and on the risk of venous thrombosis
[15].We confirmed a reduction in levels of FVIII, but this effect
was restricted to only one of the three haplotypes, HT1, inmen.
In this group, menwithHT1, a reduction in venous thrombosis
risk was observed; however, the reduction in risk could only
partially be explained through the reduction in FVIII levels
[15]. This suggested that functional variations in the FVIII
molecule may also contribute to the development of venous
thrombosis.
To investigatewhether these threeFVIIIgenehaplotypes also
affect the risk of arterial thrombosis, we studied the effects of
these haplotypes in two population-based case-control studies
on myocardial infarction: Study of Myocardial Infarctions
Leiden (SMILE)andRiskofArterialThrombosis inRelation to
Oral Contraceptives study (RATIO). Both studies have been
described previously in more detail [16,17]. In brief, SMILE
consists of 560 patients, all men below the age of 70, diagnosed
with a first myocardial infarction. The control group consists of
646 men who do not have a history of myocardial infarction.
Control subjects were frequencymatched to patients on 10-year
age groups. Plasma and DNA samples were available for all
participants. RATIO consists of three substudies for different
vascular events: ischemic stroke, peripheral vascular disease and
myocardial infarction.Only patientswithmyocardial infarction
were included in the present study. Patients were 248 women
between the ages of 18 and 49 who were hospitalized for a first
myocardial infarction. For 217 of these 248women, plasma and
DNA samples were available, and these 217 women were
included in the analysis.RATIOhas one large control group for
all three substudies. This group consists of 925 women between
theagesof18and49whohadnohistoryofcoronary, cerebralor
peripheral arterial disease. The controls were selected via
random digit dialing. Plasma andDNA samples were available
for the controls (639 women), and these were included in the
current study.
In order to identify carriers of the three haplotypes HT1,
HT3 and HT5, c94901 g (numbering according to Seattle-
SNPs, April 2004 [14]; rs1800291), encoding D1241E was
determined in all individuals. Subsequently, two haplotype
tagging SNPs specific for HT3 and HT5, g24052a (rs6655259)
and g27882c (rs-number pending) respectively, were deter-
mined in both heterozygous and homozygous carriers of the
1241E encoding allele. Genotyping was performed using either
polymerase chain reaction–restriction fragment length
polymorphisms (PCR–RFLP) analyses or 5¢nuclease/Taqman
assays. This has previously been described in detail [15].
The haplotypes present in SMILE and RATIO were in
accordance with those reported by SeattleSNPs. Haplotype
frequencies were approximately 14% forHT1 and 2% for both
HT3 and HT5 in the control groups of both studies. The
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distribution of genotypes and haplotypes over case and
controls of SMILE and RATIO are depicted in Table 1.
In contrast to what we found for venous thrombosis [15],
neither the 1241E allele nor HT1 were associated with the risk
of myocardial infarction in men. In SMILE, the odds ratio
(OR) for 1241E was 1.0 [95% confidence interval (CI95)
0.8–1.4] and for HT1 the OR was 0.9 (CI95 0.7–1.3). HT5 was
rare, and an increase in risk for HT5 was observed, with anOR
of 2.7 (CI95 1.1–6.6) in hemizygous carriers of HT5. HT3 was
even less common and the risk estimate had wide confidence
intervals.
InRATIO, no clear effect of 1241E on the risk ofmyocardial
infarction in young women was observed, although the results
were compatible with a graded reduced risk, with an OR of 0.9
(CI950.6–1.3) forheterozygous1241Ecarriers andanORof0.5
(CI95 0.2–1.5) for 1241E homozygotes. This risk reduction was
most pronounced for HT1 carriers: for heterozygous women,
the ORwas 0.8 (CI95 0.6–1.2) and for homozygous women the
OR was 0.2 (0.02–1.2). In accordance with the increase in risk
observed in hemizygous men for HT5, the risk of myocardial
infarction appeared to be increased slightly in women hetero-
zygous for HT5, with an OR of 1.5 (CI95 0.7–3.2).
Previously, we reported on a reduction of risk of venous
thrombosis in male carriers of the HT1 haplotype; this is one of
the three haplotypes on which the D1241E variant is
found, which is associated with reduced factor VIII plasma
levels [15]. In the current analysis we find no association of this
haplotype with the occurrence of myocardial infarction in men,
while it was associated with a reduced risk of myocardial
infarction in young women. It is surprising that an association
between HT1 and the risk of myocardial infarction was
observed in women and not in men, whereas for venous
thrombosis the opposite is true. It is possible that in younger
individuals, such as the women in RATIO, coagulation plays a
more important role in the development of arterial disease,
whereas in older individuals, such as most patients of SMILE,
arterial endothelial damage is the more important trigger of a
myocardial infarction. However, this study again indicates an
association between the FVIII gene HT1 and thrombotic
disease. HT3 and HT5 were rare in our study populations.
Because of wide confidence intervals, no firm conclusions can
be drawn. However, increases in the risk of myocardial
infarction were observed in carriers of these 1241E encoding
haplotypes. These results need to be confirmed in other studies.
Because effects were different between the three haplo-
types, these results indicate that D1241E itself is not a
functional variation but, in all likelihood, it is merely linked
to other functional FVIII gene variations. This observation is
in agreement with the different effects that these three
haplotypes have on levels of FVIII in SMILE and RATIO
and also in the Leiden Thrombophilia Study (LETS), as
reported previously. HT1 was associated with reduced levels
of FVIII in men, whereas HT3 and HT5 showed no effect on
levels [15].
In conclusion, this study indicates that FVIII gene variations
may influence the risk of arterial thrombosis.
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We have recently published the results of a meta-analysis
performed by pooling available information on thrombotic
complications in children with acute lymphoblastic leukemia
(ALL) [1]. During induction treatment in 1280 children from 17
prospective studies, the rate of thrombosis was 4.8% (95% CI
3.7–6.0). Lower doses of asparaginase (ASP) for long periods
were associated with the highest incidence of thrombosis, as
were anthracyclines and prednisone (instead of dexametha-
sone). The presence of central lines and of thrombophilic
genetic abnormalities also appeared to be frequently associated
with thrombosis.
After these findings, we felt of interest to explore the rate of
thrombosis in adults with ALL, along with the factors
associated with this complication.
For this purpose, we pooled all available data on thrombosis
affecting adulthood ALL in the PUBMED database, using the
same search strategy and statistic methods as described [1].
Thirteen prospective studies performed on adults during the
induction treatment of ALL were retrieved [2–14]. Seven were
specifically designed to evaluate clinical thrombosis, whereas
the remaining sixwere planned to study hypercoagulability, but
also described the occurrence of clinical events.
Thrombosis rate was separately estimated for different
subgroups of studies, which were created taking into account:
differences in treatment (type and dose of ASP, type of steroids
and use of anthracyclines) and year of publication of the study.
Pooled incidence rates (IRs) were calculated using an exact
method [1]. The method provides stratum-specific estimates
and test of differences across subgroups.
The pooled population included 323 patients and 19 events
taking place during the induction phase (Incidence: 5.9%; 95%
CI: 3.5–9.2). Deep vein thrombosis originating in the lower
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